Acute Renal Failure and Intravenous Immune Globulin

Perazella, Mark A.; Cayco, Antonio V.

doi:10.1097/00045391-199811000-00008

Cited by 16 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, the underlying mechanism is not clear. One could speculate that this side effect is caused by the stabilizing substances contained in the IVIg preparations as has been reported for acute renal failure [1,11]. The preparations associated with liver enzyme elevation contain sucrose and PEG/sorbitol, while the preparation not causing a significant liver enzyme elevation contains glycine.…”

Section: Discussionmentioning

confidence: 87%

Side effects of intravenous immunoglobulins in neurological autoimmune disorders

et al. 2003

View full text Add to dashboard Cite

The increased use of intravenous immunoglobulins (IVIg) in the treatment of neurological autoimmune diseases has led to more awareness of adverse reactions. We studied prospectively the side effects of IVIg during 84 treatment courses with a total of 341 infusions under routine clinical conditions. Mild reactions were common. Headache was noted most often, occurring during 30% of treatment courses. There were three severe adverse events (3.6% of all treatment courses) that led to discontinuation of the treatment, namely thrombosis of the jugular vein, allergic reaction and retrosternal pressure. Significant changes in laboratory findings were seen for leucocytes, erythrocytes, haematocrit, haemoglobin, ALAT and ASAT. None of these changes were clinically relevant. The elevation of liver enzymes was dependent on the IVIg preparation used, while there was no association with the underlying disease, age, or gender of the patient. In conclusion, this prospective study confirms the high frequency of mild, self-limited side effects of IVIg. Elevation of liver enzymes may possibly be associated with certain IVIg preparations. Bearing these complications in mind, this prospective study supports the notion that IVIg can generally be regarded as safe, leading to severe adverse events during only 3 (0.9%) of 341 infusions (or 3 of 84 treatment courses, 3.6 %). However, careful monitoring for severe side effects remains mandatory, and we propose that laboratory findings like full blood count, renal and liver function should be monitored routinely.

show abstract

Section: Discussionmentioning

confidence: 87%

Side effects of intravenous immunoglobulins in neurological autoimmune disorders

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Acute renal failure is usually oliguric and reversible and has been related to osmotic injury secondary to sucrose. The majority of cases of renal dysfunction occurred in the first 10 days after the first cycle of IVIg therapy [122][123][124].…”

Section: Page 21 Of 47mentioning

confidence: 99%

Immunoglobulin treatment in primary antibody deficiency

Maarschalk-Ellerbroek

Hoepelman

Ellerbroek

2011

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

The primary antibody deficiency syndromes are characterised by recurrent respiratory tract infections and the inability to produce effective immunoglobulin (Ig) responses. The best known primary antibody deficiencies are common variable immunodeficiency (CVID), X-linked agammaglobulinaemia (XLA), immunoglobulin G (IgG) subclass deficiency, and selective antibody deficiency with normal immunoglobulins (SADNI).Therapy in these patients consists of prophylactic antibiotics and/or Ig replacement therapy. Diagnostic delay remains common owing to limited awareness of the presenting features and may result in increased morbidity and mortality. Replacement therapy with immunoglobulins increases life expectancy and reduces the frequency and severity of infections, but the effect on end-organ damage is still unknown. Both intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) treatment appear to be safe, with comparable efficacy. A starting dose of 300-400 mg/kg/month in IVIg and 100 mg/week for SCIg is recommended. IgG trough levels should be >5 g/L for patients with agammaglobulinaemia and 3 g/L greater than the initial IgG level for patients with CVID; however, the clinical response should be foremost in choosing the dose and trough level. Infusion-related adverse reactions are generally mild owing to improved manufacturing processes. In this paper, aspects of Ig replacement therapy in primary antibody-deficient patients will be addressed.

show abstract

“…Hyperviscosity may be one possible explanation for some of the more severe adverse events, as at least some IGIV preparations can potentially increase viscosity, which impedes capillary flow [8,[12][13][14][15][16]. Risk factors for developing hyperviscosity include higher doses of IGIV, faster rates of infusion, and a series of patient risk factors including elderly patients with low cardiac output, preexisting vascular disease, hypergammaglobulinemia, cryoglobulinemia, and hypercholesterolemia ( Table 7).…”

Section: Matching Patient Needs Risks and Selection Of Igivmentioning

confidence: 99%

Differences between IGIV products: Impact on clinical outcome

Gelfand

2006

International Immunopharmacology

View full text Add to dashboard Cite

Acute Renal Failure and Intravenous Immune Globulin

Cited by 16 publications

References 0 publications

Side effects of intravenous immunoglobulins in neurological autoimmune disorders

Side effects of intravenous immunoglobulins in neurological autoimmune disorders

Immunoglobulin treatment in primary antibody deficiency

Differences between IGIV products: Impact on clinical outcome

Contact Info

Product

Resources

About